Las enfermedades raras y los medicamentos huérfanos, su reconocimiento y protagonismo a lo largo del siglo XX
DOI:
https://doi.org/10.14195/1647-6336_14_8Keywords:
Rare disease, Orphan disease, Orphan drugs, Drugs of limited commercial valueAbstract
The regulation of orphan drugs in the EU is implemented by the approval of the EC Regulation 141/2000. Nevertheless, up to its publication, there was a difficult way to go, a fact which had already become clear in the late eighteenth century through publications and letters in journals of scientific character. Thus, we considered analyzing the evolution of the denominations 'rare disease' and 'orphan drug, their scope, and the problems which preceded the approval of the regulation; and furthermore, assessing the impact of the proposals on governmental actions and on the regulation which has been approved.
Downloads
Downloads
Published
How to Cite
Issue
Section
License
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows sharing the work with recognition of authorship and initial publication in Antropologia Portuguesa journal.
